Abstract: The present invention relates to modified glass fiber membranes which exhibit sufficient hydrophilicity and sufficient electropositivity to bind DNA from a suspension containing DNA and permit elution of the DNA from the membrane. Generally, the hydrophilic and electropositive characteristics are expressed at the surface of the modified glass fiber membrane. Preferred modified glass fiber membranes of the present invention include glass fiber membranes that have been modified by treatment with trifluoroacetic acid (TFA), BCl.sub.3, SiCl.sub.4, NaOH, F.sup.-, AlCl.sub.3 alone or in combination, with or without water. The modified glass fiber membranes of the present invention are particularly useful in processes for purification of DNA from other cellular components.

Abstract: The present invention relates to modified glass fiber membranes which exhibit sufficient hydrophilicity and sufficient electropositivity to bind DNA from a suspension containing DNA and permit elution of the DNA from the membrane. Generally, the hydrophilic and electropositive characteristics are expressed at the surface of the modified glass fiber membrane. Preferred modified glass fiber membranes of the present invention include glass fiber membranes that have been modified by treatment with trifluoroacetic acid (TFA), BCl.sub.3, SiCl.sub.4, NaOH, F.sup.-, AlCl.sub.3 alone or in combination, with or without water. The modified glass fiber membranes of the present invention are particularly useful in processes for purification of DNA from other cellular components.

Abstract: The present invention concerns an improved process of making d4T from 5-MU. Another aspect of the invention relates to useful intermediates produced during the process.

Abstract: This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease states.

Abstract: The present invention relates to modified glass fiber membranes which exhibit sufficient hydrophilicity and sufficient electropositivity to bind DNA from a suspension containing DNA and permit elution of the DNA from the membrane. Generally, the hydrophilic and electropositive characteristics are expressed at the surface of the modified glass fiber membrane. Preferred modified glass fiber membranes of the present invention include glass fiber membranes that have been modified by treatment with trifluoroacetic acid (TFA), BCl.sub.3, SiCl.sub.4, NaOH, F.sup.-, AlCl.sub.3 alone or in combination, with or without water. The modified glass fiber membranes of the present invention are particularly useful in processes for purification of DNA from other cellular components.

Abstract: An etoposide phosphate represented by the formula (1): ##STR1## is prepared by blocking the hydroxyl groups of the saccharide moiety of etoposide with halogenoacetyl groups, thereafter phosphorylating the 4'-position, and removing the halogenoacetyl groups from the obtained phosphate in the presence of an amine.This process can give the objective etoposide phosphate in a higher yield than that of the prior art to enable the industrial mass-production thereof.

Abstract: A novel process for producing chiral hydroxylamines for use as intermediates to make chiral hydroxyureas, which process comprises a tandem condensation-cyclization reaction between a dimethylsulfoxoniurn methylide and an appropriately substituted nitrone bearing a D- or L- mannose chiral auxiliary to yield a compound of Formula (I) as claimed herein.

Abstract: Adenosine A.sub.2 agonists of the formula ##STR1## wherein R is hydrogen, alkyl, cycloalkyl or phenylalkyl;R.sub.1 is selected from the group consisting ofa) optionally substituted phenyl or naphthyl;b) --(CH.sub.2).sub.m --Het wherein m is 0-3 and Het is a 5 or 6 membered heterocyclic aromatic or non-aromatic ring, optionally benzocondensed;c) cycloalkyl optionally containing unsaturations or alkenyl; and ##STR2## wherein n is 0-4; R.sub.2 is hydrogen, methyl or phenyl;R.sub.5 is hydrogen, alkyl, cycloalkyl, cycloalkenyl or phenylalkyl; or R.sub.2 and R.sub.5 form a 5 or 6-membered carbocyclic ring; or R.sub.5 is hydrogen and R.sub.2 and R.sub.4 form an oxo group or a corresponding acetalic derivative;R.sub.4 is OH, NH.sub.2, dialkylamino, halogen or cyano; andR.sub.3 is alkyl, cycloalkyl, phenyl or benzyl; provided that when R is different from hydrogen or when R is hydrogen and R.sub.3 is phenyl or benzyl, R.sub.

Abstract: 2'-Deoxy-4'-thio-ribonucleosides, intermediates in their production, and their use as antiviral and anticancer agents are disclosed.

Abstract: Support system for the synthesis of oligonucleotides wherein the first nucleoside is bound to the support via a silylether linkage, especially of the formula ##STR1## wherein B is a nucleoside or deoxynucleoside base.R.sub.1 is a protecting group.R.sub.2 is --H, --OH, or --OR.sub.5, in which R.sub.5 is a protecting group.R.sub.3, R.sub.4 and X each represent alkyl, aryl, cycloalkyl, alkenyl, aralkyl, cycloalkylalkyl, alkyloxy, aryloxy, cycloalkyloxy, alkenyloxy, aralkyloxy.S is a solid support, whereby not more than one of R.sub.3, R.sub.4 and X represent alkyloxy, aryloxy, cycloalkyloxy, alkenyloxy, aralkyloxy or cycloalkylalkyloxy.

Abstract: Alkyl glycosides are prepared by reacting alcohols with monosaccharides or compounds which, under the reaction conditions, form monosaccharides, in the presence of amphoteric surfactants in the acid form as catalysts, and subsequently neutralizing the reaction mixture with bases.

Abstract: Nucleoside thiotriphosphates carrying .sup.32 P in the gamma-thiophosphate group, prepared by reaction between a nucleoside diphosphate and a .sup.32 P labelled thiophosphate salt, are used as thiophosphorylating agents for antibodies that bind to tumour-associated antigens. The labelled thiotriphosphates can be used to introduce a therapeutically useful .sup.32 P atom into an antibody that has been modified by the incorporation into its structure of a peptide region capable of acting as a substrate for a phosphokinase. The resulting labelled antibody can then be used for injection in anti-tumour therapy and has clinical advantages over the corresponding phosphorylated analogue.

Abstract: Disclosed herein are surface activated, organic polymers useful for biopolymer synthesis. Most preferably, aminated polypropylene is used for the synthesis of oligonucleotides thereto, and these devices are most preferably utilized for genetic analysis of patient samples.

Abstract: A method of making a radiolabeled pyrimidine nucleoside or nucleotide is described. In the method an aqueous solution (i) a radioactive iodide, bromide, chlorine or astatide ion and (ii) a water soluble halomercuri pyrimidine nucleoside or nucleotide is contacted with an oxidizing agent, whereby a water soluble pyrimidine nucleoside or nucleotide labeled with radioactive iodine, bromine, chlorine or astatine is formed. Kits suitable for practicing the method are also disclosed.

Abstract: The present invention is directed to methods of reducing the degree of inflammation arising from a secondary immune response in a mammal due to antigen exposure (challenge) by the administration of valienamine-related disaccharide compounds and the pharmaceutical compositions employed in the method.

Abstract: This invention provides a compound having the structure: ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are same or different, and are hydrogen, hydroxyl, or fluorine; Z is O, CH.sub.2 or CF.sub.2 ; R is chlorine, bromine, iodine, carbonitrile, carboxylic ester, or carboxamide; and one of W, X and Y is N or N.sup.+ R', wherein R' is methyl or ethyl, and all others are CH; provided that R.sup.1 is not H when R.sup.2 and R.sup.3 are OH, Z is O, R is carboxamide and W is N or N.sup.+ R'.This invention also provides methods of preparing the compounds and a method of treating a mammal having a NAD-dependent enzyme associated disorder.

Abstract: Novel hydrogen-phosphonodithioate compositions are provided which are particularly useful for forming internucleotide and internucleoside linkages in oligonucleosides or oligonucleotides, The oligonucleotides and analogs thereof made by using the hydrogen-phosphonodithioate compositions may be therapeutically useful as antiviral and anticancer agents and may have other therapeutic or diagnostic uses, A method for making the hydrogen-phosphonodithioates is provided as well as a method for converting same to an activated intermediate for substitution on the phosphorus atom.

Abstract: A process for producing a sucrose fatty acid ester wherein the sucrose fatty acid ester is recovered from a reaction mixture prepared by reacting sucrose with a fatty acid alkyl ester in the presence of an alkali catalyst by using dimethyl sulfoxide as a reaction solvent, the process comprising: (i) subjecting the reaction mixture to a first liquid-liquid extraction by using a hardly water-miscible organic solvent, which is selected from an alcohol having at least 4 carbon atoms and a ketone having at least 4 carbon atoms, and water as extractants, with regulating the pH value of an aqueous phase to 3 to 7.

Abstract: The compounds 5'-deoxy-5'-(hydroxyethylthio)adenosine (HETA); 5'-deoxy-5'-(monofluoroethylthio)adenosine (MFETA); 5'-deoxy-5'-(chloroethylthio)adenosine (CETA); 5'-deoxy-5'-(bromoethylthio)adenosine (BETA); 5-deoxy-5-(monofluoroethylthio)ribose (MFETR); 5-deoxy-5-(chloroethylthio)ribose (CETR); 5-deoxy-5-(bromoethylthio)ribose (BETR) and 5-deoxy-5-(hydroxyethylthio)ribose (HETR), are described as well as their uses in treating infections caused by 5'-deoxy-5'-methylthioadenosine (MTA) phosphorylase-containing pathogenic microorganisms; in treating infections caused by 5-deoxy-5-methylthioribose (MTR) kinase-containing pathogenic microorganism; and for treating neoplastic diseases.

Abstract: A process for the synthesis of peracyl-1-O-steroidal-.beta.-cellobiosides that provides excellent .beta.-anomeric selectivity without the use of a metal salt promoter. The process comprises reacting heptaacyl-.beta.-D-cellobiosyl-1-fluoride and a trisubstituted silyl-3-O-steroid, wherein the steroid is tigogenin, hecogenin, 11-ketotigogenin or diosgenin in the absence of a metal salt under suitable conditions.